Canopy Growth (CGC) vs Definium Therapeutics (DFTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Definium Therapeutics (DFTX) has outperformed Canopy Growth (CGC) over the past year, gaining 193.1% versus a loss of 39.6%. Over five years, DFTX leads with a -0.5% price change compared with -99.3% for CGC. Definium Therapeutics is the larger company by market cap ($4.46 billion vs $372.6 million), about 12.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CGC | DFTX |
|---|---|---|
| Share price | $0.8292 | $33.20 |
| Market cap | $372.56M | $4.46B |
| 1-day change | -5.40% | -5.39% |
| YTD return | -23.11% | +162.06% |
| 1-year return | -39.55% | +193.15% |
| 5-year return | -99.34% | -0.45% |
| EPS (TTM) | $-0.45 | $-3.43 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | — | $-183.79M |
| 52-week high | $2.38 | $49.70 |
| 52-week low | $0.81 | $10.47 |
| Distance from 52-week high | -65.16% | -33.20% |
| Analyst consensus | none | none |
| Avg. price target upside | +43.51% | +115.81% |
| Average volume | 2.75M | 2.14M |
| Shares outstanding | 423.04M | 134.37M |
| Employees | 1,128 | 105 |
| Sector | Health Care | Health Care |
| Industry | Medicinal Chemicals and Botanical Products | Medicinal Chemicals and Botanical Products |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Definium Therapeutics is about 12.0 times larger than Canopy Growth by market value ($4.46B vs $372.56M).
- DFTX has outperformed CGC by 232.7 percentage points over the past year.
About Canopy Growth
CGC stock →Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and cannabis-related products for medical and adult use in Canada, Germany, the United States, and internationally. The company operates through two segments, Cannabis and Storz & Bickel.
Health Care · Medicinal Chemicals and Botanical Products · 1,128 employees
About Definium Therapeutics
DFTX stock →Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder.
Health Care · Medicinal Chemicals and Botanical Products · 105 employees
CGC vs DFTX FAQ
Which is bigger, Canopy Growth or Definium Therapeutics?
Definium Therapeutics (DFTX) is larger, with a market capitalization of $4.46B compared with $372.56M for Canopy Growth (CGC).
Which stock has performed better over the past year, CGC or DFTX?
DFTX returned +193.15% over the past 12 months, compared with -39.55% for CGC (price return, excluding dividends). Past performance does not predict future results.
Are Canopy Growth and Definium Therapeutics in the same industry?
Yes. Both are classified in the Medicinal Chemicals and Botanical Products industry within the Health Care sector.